Home > Boards > US Listed > Medical - Drugs > Abbvie (ABBV)

News: $ABBV AbbVie Reports Full-Year and Fourth-Quarter 2018

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
whytestocks Member Profile
Member Level 
Followed By 24
Posts 3,329
Boards Moderated 0
Alias Born 06/04/18
160x600 placeholder
New Long-Term Data from Upadacitinib Phase 3 Studies in Rheumatoid Arthritis Including Results on Clinical Remission at 48 We... PR Newswire (US) - 6/12/2019 6:00:00 PM
New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance PR Newswire (US) - 6/11/2019 7:00:00 AM
AbbVie's MAVIRET™ now listed on the Nova Scotia and Manitoba formularies PR Newswire (Canada) - 6/10/2019 8:00:00 AM
AbbVie to Present at the Goldman Sachs Global Healthcare Conference PR Newswire (US) - 6/7/2019 8:00:00 AM
AbbVie reçoit une recommandation favorable du Comité d'experts en examen du Programme pancanadien d'évaluation des antican... PR Newswire (Canada) - 6/6/2019 9:00:00 AM
AbbVie Receives Positive Recommendation from the pan-Canadian Oncology Drug Review Expert Review Committee for the Combinatio... PR Newswire (Canada) - 6/6/2019 9:00:00 AM
AbbVie Presents Data from Venetoclax Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lym... PR Newswire (US) - 6/4/2019 11:09:00 AM
Specialized Disclosure Report (sd) Edgar (US Regulatory) - 5/31/2019 5:01:56 PM
AbbVie Presents Results from Several Studies and Clinical Trials Investigating Medicines Across More than 15 Cancers at the 2... PR Newswire (US) - 5/30/2019 8:45:00 AM
MAVIRET(MC) d'AbbVie maintenant inscrit sur la liste des médicaments du Nouveau-Brunswick PR Newswire (Canada) - 5/30/2019 8:00:00 AM
AbbVie's MAVIRET™ now listed in New Brunswick PR Newswire (Canada) - 5/30/2019 8:00:00 AM
Johnson & Johnson Weighs on Pharmaceutical ETFs Dow Jones News - 5/29/2019 2:30:00 PM
AbbVie conclut une entente avec l'Alliance pancanadienne pharmaceutique (APP) concernant VENCLEXTA®, un traitement de la leu... PR Newswire (Canada) - 5/23/2019 9:00:00 AM
AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for VENCLEXTA®, a treatment for chronic lym... PR Newswire (Canada) - 5/23/2019 9:00:00 AM
AbbVie met sur le marché la dose d'ORILISSA(MC) (élagolix) à 200 mg deux fois par jour pour le traitement des douleurs mod... PR Newswire (Canada) - 5/21/2019 8:00:00 AM
AbbVie Launches ORILISSA™ (elagolix) 200 mg BID Dose for the Treatment of Moderate to Severe Pain Associated with Endometri... PR Newswire (Canada) - 5/21/2019 8:00:00 AM
AbbVie Glioblastoma Drug Misses Primary Endpoint Dow Jones News - 5/17/2019 9:31:00 AM
AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, ... PR Newswire (US) - 5/17/2019 8:45:00 AM
Genentech Says FDA Approves Venclexta Plus Gazyva for Chronic Lymphocytic Leukemia Dow Jones News - 5/15/2019 3:30:00 PM
AbbVie Announces US FDA Approval of VENCLEXTA® (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untrea... PR Newswire (US) - 5/15/2019 2:19:00 PM
Drugmakers Settle U.S. Patent Dispute Over Clone of Humira -- WSJ Dow Jones News - 5/15/2019 3:02:00 AM
AbbVie, Boehringer Ingelheim in U.S. Settlement on Humira Biosimilar -- Update Dow Jones News - 5/14/2019 12:16:00 PM
MC10, Inc. and AbbVie (NYSE:ABBV) Announce Clinical Trials in Multiple Sclerosis Using the BioStamp nPoint® System Business Wire - 5/14/2019 10:13:00 AM
AbbVie, Boehringer Ingelheim in U.S. Settlement on Humira Biosimilar Dow Jones News - 5/14/2019 9:53:00 AM
AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim PR Newswire (US) - 5/14/2019 8:34:00 AM
whytestocks Member Level  Friday, 01/25/19 07:46:30 AM
Re: None
Post # of 430 
News: $ABBV AbbVie Reports Full-Year and Fourth-Quarter 2018 Financial Results

NORTH CHICAGO, Ill., Jan. 25, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2018. "We delivered exceptional performance in 2018, including operational revenue growth of more than 15 percent and E...

Got this from https://marketwirenews.com/news-releases/abbvie-reports-full-year-and-fourth-quarter-2018-financial-results-7550922.html

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist